The purpose of this study is to determine whether carotid surgery combined with optimal medical therapy improves long-term survival free of ipsilateral stroke in patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke when compared with optimal medical therapy alone.
Carotid artery stenosis \>= 50% affects about 3% of subjects \>= 60 years and accounts for up to 15% of all ischemic strokes. Overall, patients with asymptomatic carotid stenosis have a low risk of ipsilateral stroke on modern medical therapy. It is therefore uncertain whether the benefit of carotid surgery still justifies the perioperative risk of stroke or death, and whether revascularisation is good value for money considering competing demands on health services. Several imaging techniques have been developed to identify patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke. Specifically, the presence of transcranial Doppler (TCD)-detected embolic signals, intraplaque haemorrhage on magnetic resonance imaging, TCD-measured impaired cerebral vasomotor reserve or rapid stenosis progression have all been shown to involve an at least 3-fold higher risk of ipsilateral stroke. However, before recommendations for clinical practice can be made regarding the use of these tools, their utility must be demonstrated in a formal randomised clinical trial. Our hypothesis is that the use of these predictors can identify a subset of patients with asymptomatic carotid stenosis who could benefit from prophylactic endarterectomy. Carotid endarterectomy The procedure will be carried out with the technique routinely used by each surgeon. Operative reports and perioperative complications will be collected. CEA will have to be performed as soon as possible, within 60 days after randomization. Optimal medical therapy OMT will be applied to all patients and started immediately after randomisation. OMT will be defined by the adhoc committee and follow relevant guidelines. It will include: * Antiplatelet therapy. If the patient requires anticoagulation for any reason (e.g. atrial fibrillation), the patient should be treated with an appropriate anticoagulant according to the practice at the centre as an alternative to antiplatelet therapy. * Antihypertensive treatment, if required, to achieve a target blood pressure \< 140/90 mmHg (higher targets may be defined by the OMT committee for selected conditions, e.g. contralateral carotid occlusion) Application of structured programs, such as stepped-care approach using ranking of antihypertensive drugs will be used. * High-dose statin treatment (target LDL \< 0.7 g/l). A stepped-care approach with raking of lipid-lowering drugs will also be used. * Patients smoking at the time of randomisation will be encouraged to stop and join a smoking cessation and support program. * Other lifestyle modification: reduction of alcohol consumption, choosing healthy food, increasing regular physical activity, reduction of body weight if relevant. OMT may be modified during the course of the trial to take account revised guidelines or new evidence.
Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
Optimal medical therapy alone
Centre Hospitalier régional de Besançon, Hôpital Jean Minjoz
Besançon, France
CHU Bordeaux, Groupe Hospitalier Pellegrin
Ipsilateral stroke or procedural stroke or death
Any ipsilateral stroke within 6 years after randomization or procedural (within 30 days after revascularization) stroke or death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any stroke or procedural death
Any stroke within 6 years after randomization or procedural death (within 30 days after revascularization)
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any disabling or fatal stroke or procedural death
Any disabling or fatal stroke within 6 years after randomization or procedural death (within 30 days after revascularization)
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any stroke or TIA or procedural death
Any stroke or TIA within 6 years after randomization or procedural death within 6 years after randomization
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any stroke or death
Any stroke or death within 6 years after randomization
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Myocardial infarction
Myocardial infarction within 6 years after randomization
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any death
Any death within 6 years after randomization
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
43
Bordeaux, France
CHRU La Cavale Blanche
Brest, France
Hôpital Gabriel Montpied
Clermont-Ferrand, France
CHU Henri Mondor
Créteil, France
CHU Dijon-Bourgogne
Dijon, France
CHU de Grenoble
Grenoble, France
Hôpital Mignot - CH Versailles
Le Chesnay, France
CHRU de Lille
Lille, France
Hôpital Neurologique Pierre Wertheimer GHE
Lyon, France
...and 13 more locations
Cardiovascular death
Cardiovascular death within 6 years after randomization
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any hospitalisation for vascular disease
Any hospitalisation for vascular disease within 6 years after randomization
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Cranial nerve palsy attributed to revascularisation
Cranial nerve palsy attributed to revascularisation within 30 days after revascularization
Time frame: M1
Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay
Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay within 30 days after revascularization
Time frame: M1
Further revascularisation of the randomised artery after the initial attempt.
Further revascularisation of the randomised artery after the initial attempt.
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Carotid revascularisation
Carotid revascularisation during follow-up other than that allocated at randomisation
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
New cerebral infarction or haemorrhage
New cerebral infarction or haemorrhage on MRI at 2 years
Time frame: M24
Increase in white-matter changes
Increase in white-matter changes on MRI at 2 years.
Time frame: M0, M24
Cognitive impairment
Cognitive impairment assessed by the Montreal Cognitive Assessment (MoCA) with adjustment for demographic factors.
Time frame: M0, M24
Depression
Depression measured by the Centre for Epidemiologic Studies Depression (CES-D) Scale.
Time frame: M0, M24
Health-related quality of life
Health-related quality of life measured using the European Quality Of Life (EQ-5D).
Time frame: M0, M24
Disability
Disability measured by the modified Rankin scale with structured interview
Time frame: M0, M24
Achievement of goals for each of the components of optimal medical treatment
Achievement of goals for each of the components of optimal medical treatment
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72